Shots:

• The EMA’s ODD is based on P-II/III study assessing RT001 in patients with INAD- a neurodegeneration associated with PLA2G6
• EMA’s ODD is granted to the drug offering treatments for rare- devastating- fatal- and untreated diseases affecting fewer than 200-000 people or >200-000 persons
• Retrotope’s RT001 is an oral deuterated polyunsaturated fatty acid (D-PUFA) working against PUFA to prevent cell death

Ref: Retrotope | Image: PRNewswire